Iptakalim, a vascular ATP-sensitive potassium (KATP) channel opener, closes rat pancreatic β-cell KATP channels and increases insulin release

Journal of Pharmacology and Experimental Therapeutics

Volumn 322, Issue 2, 2007, Pages 871-878

  Misaki, Naoko ^a   Mao, Xia ^b   Lin, Yu Fung ^b   Suga, Sechiko ^a   Li, Guo Hui ^c   Liu, Qiang ^c   Chang, Yongchang ^c   Wang, Hai ^d   Wakui, Makoto ^a   Wu, Jie ^c,d  

^a HIROSAKI UNIVERSITY   (Japan)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BARROW NEUROLOGICAL INSTITUTE   (United States)

^d BEIJING INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; IPTAKALIM;

ANIMAL CELL; ARTICLE; CALCIUM CELL LEVEL; CELL FUNCTION; CONTROLLED STUDY; EMBRYO; EXCITABILITY; HUMAN; HUMAN CELL; IMAGING; INSULIN RELEASE; NONHUMAN; OOCYTE; PANCREAS ISLET BETA CELL; PATCH CLAMP; PRIORITY JOURNAL; RAT; SENSITIVITY ANALYSIS; XENOPUS;

ANIMALS; CALCIUM; CELL LINE; CELLS, CULTURED; DIAZOXIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GLUCOSE; HUMANS; INSULIN; INSULIN-SECRETING CELLS; ION CHANNEL GATING; MEMBRANE POTENTIALS; NIFEDIPINE; OOCYTES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS, INWARDLY RECTIFYING; PROPYLAMINES; RATS; TOLBUTAMIDE; XENOPUS LAEVIS;

EID: 34547122225     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.121129     Document Type: Article

References (38)

1. Aguilar-Bryan L, Nichols CG, Wechsler SW, Clement JP 4th, Boyd AE 3rd, Gonzalez G, Herrera-Sosa H, Nguy K, Bryan J, and Nelson DA (1995) Cloning of the beta cell high-affinity sulfonylurea receptor: a regulator of insulin secretion. Science 268:423-426.
2. Ashcroft FM (2006) K(ATP) channels and insulin secretion: a key role in health and disease. Biochem Soc Trans 34:243-246.
3. Ashfield R, Gribble FM, Ashcroft SJ, and Ashcroft FM (1999) Reduction of dapsone hydroxylamine to dapsone during methaemoglobin formation in human erythrocytes in vitro. III: Effect of diabetes. Diabetes 48:1341-1347.
4. Avshalumov MV, Chen BT, Koos T, Tepper JM, and Rice ME (2005) Endogenous hydrogen peroxide regulates the excitability of midbrain dopamine neurons via ATP-sensitive potassium channels. J Neurosci 25:4222-4231.
5. Brady PA and Terzic A (1998) The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol 31:950-956.
6. Chutkow WA, Simon MC, Le Beau MM, and Burant CF (1996) Extrahepatic manifestations of hepatitis C among United States male veterans. Diabetes 45:1439-1445.
7. Cui Y, Tinker A, and Clapp LH (2003) Different molecular sites of action for the KATP channel inhibitors, PNU-99963 and PNU-37883A. Br J Pharmacol 139:122-128.
8. Engler RL and Yellon DM (1996) Sulfonylurea KATP blockade in type II diabetes and preconditioning in cardiovascular disease: time for reconsideration. Circulation 94:2297-2301.
9. Gribble FM and Ashcroft FM (2000a) Sulfonylurea sensitivity of adenosine triphosphate-sensitive potassium channels from beta cells and extrapancreatic tissues. Metabolism 49:3-6.
10. Gribble FM and Ashcroft FM (2000b) Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J Diabetes Complicat 14:192-196.
11. Gribble FM, Loussouarn G, Tucker SJ, Zhao C, Nichols CG, and Ashcroft FM (2000) A novel method for measurement of submembrane ATP concentration. J Biol Chem 275:30046-30049.
12. Gribble FM and Reimann F (2003) Sulphonylurea action revisited: the post-cloning era. Diabetologia 46:875-891.
13. Gribble FM, Tucker SJ, and Ashcroft FM (1997) The interaction of nucleotides with the tolbutamide block of cloned ATP-sensitive K+ channel currents expressed in Xenopus oocytes: a reinterpretation. J Physiol 504:35-45.
14. Gromada J, Dissing S, Kofod H, and Frokjaer-Jensen J (1995) Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia 38:1025-1032.
15. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440-3450.
16. Hansen JB (2006) Towards selective Kir6.2/SUR1 potassium channel openers, medicinal chemistry and therapeutic perspectives. Curr Med Chem 13:361-376.
17. ATP channels. J Pharmacol Exp Ther 291:1372-1379.
18. Inagaki N, Gonoi T, Clement JP, Wang CZ, Aguilar-Bryan L, Bryan J, and Seino S (1996) A family of sulphonylurea receptors determines the pharmacological properties of ATP-sensitive K+ channels. Neuron 16:1011-1017.
19. Klamann A, Sarfert P, Launhardt V, Schulte G, Schmiegel WH, and Nauck MA (2000) Myocardial infarction in diabetic vs. non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (glibenclamide). Eur Heart J 21:220-229.
20. Lawrence CL, Proks P, Rodrigo GC, Jones P, Hayabuchi Y, Standen NB, and Ashcroft FM (2001) Gliclazide produces high-affinity block of KATP channels in mouse isolated pancreatic beta cells but not rat heart or arterial smooth muscle cells. Diabetologia 44:1019-1025.
21. Lin YF, Jan YN, and Jan LY (2000) Regulation of ATP-sensitive potassium channel function by protein kinase A-mediated phosphorylation in transfected HEK 293 cells. EMBO J 19:942-955.
22. Liss B, Bruns R, and Roeper J (1999a) Alternative sulfonylurea receptor expression defines metabolic sensitivity of K-ATP channels in dopaminergic midbrain neurons. EMBO J 18:833-846.
23. Liss B, Neu A, and Roeper J (1999b) The weaver mouse gain-of-function phenotype of dopaminergic midbrain neurons is determined by coactivation of wvGirk2 and K-ATP channels. J Neurosci 19:8839-8848.
24. Malaisse WJ (1995) Non-insulin-dependent diabetes mellitus and islet B-cell mitochondrial glycerophosphate dehydrogenase deficiency. Diabet Med 12:479-481.
25. Mannhold R (2004) KATP channel openers: structure-activity relationships and therapeutic potential. Med Res Rev 24:213-266.
26. Mukai E, Ishida H, Horie M, Noma A, Seino Y, and Takano M (1998) The antiarrhythmic agent cibenzoline inhibits KATP channels by binding to Kir6.2. Biochem Biophys Res Commun 251:477-481.
27. + channel activity in acetylcholine-induced activation of rat pancreatic β-cells. Endocrinology 143:569-576.
28. Nourparvar A, Bulotta A, Di Mario U, and Perfetti R (2004) Novel strategies for the pharmacological management of type 2 diabetes. Trends Pharmacol Sci 25:86-91.
29. Proks P and Ashcroft FM (1997) Phentolamine block of KATP channels is mediated by Kir6.2. Proc Natl Acad Sci U S A 94:11716-11720.
30. Shin JJ, Rothman J, Farag A, McFarlane SI, and Sowers JR (2003) Role of oral anti-diabetic agents in modifying cardiovascular risk factors. Minerva Med 94:401-408.
31. Suga S, Kanno T, Nakano K, Takeo T, Dobashi Y, and Wakui M (1997) GLP-I(7-36) amide augments Ba2+ current through L-type Ca2+ channel of rat pancreatic beta-cell in a cAMP-dependent manner. Diabetes 46:1755-1760.
32. Tucker SJ, Gribble FM, Zhao C, Trapp S, and Ashcroft FM. (1997) Truncation of Kir6.2 produces ATP-sensitive K channels in the absence of the sulphonylurea receptor. Nature 387:179-183.
33. Wang H (1998) ATP-sensitive potassium channel as a new target for development of antihypertensive drugs. Acta Pharmacol Sin 19:257-267.
34. Wang H (2003) Pharmacological characteristics of the novel antihypertensive drug iptakalim hydrochloride and its molecular mechanisms. Drug Dev Res 58:65-68.
35. Wang H, Long CL, and Zhang YL (2005a) A new ATP-sensitive potassium channel opener reduces blood pressure and reverses cardiovascular remodeling in experimental hypertension. J Pharmacol Exp Ther 312:1326-1333.
36. Wang H, Zhang YL, and Chen YP (2005b) Targeting small arteries of hypertensive status with novel ATP-sensitive potassium channel openers. Curr Vasc Pharmacol 3:119-124.
37. + channels in dopamine neurons from rat substantia nigra pars compacta. J Pharmacol Exp Ther 319:155-164.
38. Zhuo ML, Huang Y, Liu DP, and Liang CC (2005) KATP channel: relation with cell metabolism and role in the cardiovascular system. Int J Biochem Cell Biol 37:751-764.